Identification of dihydroorotate dehydrogenase as a relevant drugtarget for 1-hydroxyquinolones in toxoplasma gondii

Molecular and Biochemical Parasitology

Volumn 190, Issue 1, 2013, Pages 6-15

  Hegewald, Jana ^a   Gross, Uwe ^a   Bohne, Wolfgang ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

1 Hydroxyquinolone; Dihydroorotate dehydrogenase (dhodh); Drug resistance; Hdq; Toxoplasma gondii

Indexed keywords

1 HYDROXYQUINOLONE DERIVATIVE; ANTIPARASITIC AGENT; ATOVAQUONE; COMPLEMENTARY DNA; DIHYDROOROTATE DEHYDROGENASE; QUINOLONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ALLELE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA SEQUENCE; ELECTRON; ENZYME INHIBITION; IMMUNOFLUORESCENCE; MITOCHONDRIAL RESPIRATION; MUTAGENESIS; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; SACCHAROMYCES CEREVISIAE; TOXOPLASMA GONDII; WILD TYPE;

SACCHAROMYCES CEREVISIAE; TOXOPLASMA GONDII;

EID: 84879492466     PISSN: 01666851     EISSN: 18729428     Source Type: Journal    
DOI: 10.1016/j.molbiopara.2013.05.008     Document Type: Article

References (34)

1. Vallieres C, Fisher N, Antoine T, Al-Helal M, Stocks P, Berry NG, et al. HDQ, apotent inhibitor of Plasmodium falciparum proliferation, binds to the quinonereduction site of the cytochrome bc1 complex. Antimicrob Agents Chemother2012;56:3739-47.
2. Bajohr LL, Ma L, Platte C, Liesenfeld O, Tietze LF, Gross U, et al. In vitro and in vivoactivities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasmagondii. Antimicrob Agents Chemother 2010;54:517-21.
3. Saleh A, Friesen J, Baumeister S, Gross U, Bohne W. Growth inhibitionof Toxoplasma gondii and Plasmodium falciparum by nanomolar concentra-tions of 1-hydroxy-2-dodecyl-4(1H)quinolone, a high-affinity inhibitor ofalternative (type II) NADH dehydrogenases. Antimicrob Agents Chemother2007;51:1217-22. (Pubitemid 46586796)
4. Lin SS, Gross U, Bohne W. Type II NADH dehydrogenase inhibitor 1-hydroxy-2-dodecyl-4(1H)quinolone leads to collapse of mitochondrial inner-membranepotential and ATP depletion in Toxoplasma gondii. Eukaryot Cell 2009;8:877-87.
5. Eschemann A, Galkin A, Oettmeier W, Brandt U, Kerscher SHDQ. (1-Hydroxy-2-dodecyl-4(1H)quinolone), a high affinity inhibitor for mitochondrialalternative NADH dehydrogenase: evidence for a ping-pong mechanism. J BiolChem 2005;280:3138-42. (Pubitemid 40223774)
6. Seeber F, Limenitakis J, Soldati-Favre D. Apicomplexan mitochondrialmetabolism: a story of gains, losses and retentions. Trends Parasitol2008;24:468-78.
7. Lin SS, Kerscher S, Saleh A, Brandt U, Gross U, Bohne W. The Toxoplasma gondiitype-II NADH dehydrogenase TgNDH2-I is inhibited by 1-hydroxy-2-alkyl- 4(1H)quinolones. Biochim Biophys Acta 2008;1777:1455-62.
8. Lin SS, Gross U, Bohne W. Two internal type II NADH dehydrogenases of Toxo-plasma gondii are both required for optimal tachyzoite growth. Mol Microbiol2011;82:209-21.
9. Tietze LF, Ma L. Synthesis of novel 1-Hydroxyquinolones with high anti-toxoplasma activity. Heterocycles 2010;82:377-96.
10. Donald RG, Roos DS. Insertional mutagenesis and marker rescue in a pro-tozoan parasite: cloning of the uracil phosphoribosyltransferase locus fromToxoplasma gondii. Proc Natl Acad Sci U S A 1995;92:5749-53.
11. Roos DS, Donald RG, Morrissette NS, Moulton AL. Molecular tools for geneticdissection of the protozoan parasite Toxoplasma gondii. Methods Cell Biol1994;45:27-63.
12. Fox BA, Falla A, Rommereim LM, Tomita T, Gigley JP, Mercier C, et al.Type II Toxoplasma gondii KU80 knockout strains enable functional analysisof genes required for cyst development and latent infection. Eukaryot Cell2011;10:1193-206.
13. Huynh MH, Carruthers VB. Tagging of endogenous genes in a Toxoplasma gondiistrain lacking Ku80. Eukaryot Cell 2009;8:530-9.
14. Pfefferkorn ER. Characterization of a mutant of Toxoplasma gondii resistant toaphidicolin. J Protozool 1984;31:306-10. (Pubitemid 14056937)
15. White MW, Jerome ME, Vaishnava S, Guerini M, Behnke M, Striepen B. Geneticrescue of a Toxoplasma gondii conditional cell cycle mutant. Mol Microbiol2005;55:1060-71. (Pubitemid 40299177)
16. Gubbels MJ, Li C, Striepen B. High-throughput growth assay for Toxo-plasma gondii using yellow fluorescent protein. Antimicrob Agents Chemother2003;47:309-16. (Pubitemid 36070380)
17. Radke JR, White MW. Expression of herpes simplex virus thymidine kinasein Toxoplasma gondii attenuates tachyzoite virulence in mice. Infect Immun1999;67:5292-7. (Pubitemid 29455304)
18. Hortua Triana MA, Huynh MH, Garavito MF, Fox BA, Bzik DJ, Carruthers VB, et al.Biochemical and molecular characterization of the pyrimidine biosyntheticenzyme dihydroorotate dehydrogenase from Toxoplasma gondii. Mol BiochemParasitol 2012;184:71-81.
19. Zameitat E, Gojkovic Z, Knecht W, Piskur J, Loffler M. Biochemi-cal characterization of recombinant dihydroorotate dehydrogenase fromthe opportunistic pathogenic yeast Candida albicans. FEBS J 2006;273:3183-91. (Pubitemid 43990923)
20. Fox BA, Ristuccia JG, Gigley JP, Bzik DJ. Efficient gene replacements in Toxo-plasma gondii strains deficient for nonhomologous end joining. Eukaryot Cell2009;8:520-9.
21. Painter HJ, Morrisey JM, Mather MW, Vaidya AB. Specific role of mito-chondrial electron transport in blood-stage Plasmodium falciparum. Nature2007;446:88-91. (Pubitemid 46348043)
22. Davies M, Heikkila T, McConkey GA, Fishwick CW, Parsons MR, JohnsonAP. Structure-based design, synthesis, and characterization of inhibitors ofhuman and Plasmodium falciparum dihydroorotate dehydrogenases. J MedChem 2009;52:2683-93.
23. Phillips MA, Rathod PK. Plasmodium dihydroorotate dehydrogenase: a promis-ing target for novel anti-malarial chemotherapy. Infect Disord Drug Targets2010;10:226-39.
24. Rodrigues T, Lopes F, Moreira R. Inhibitors of the mitochondrial electron trans-port chain and de novo pyrimidine biosynthesis as antimalarials: the presentstatus. Curr Med Chem 2010;17:929-56.
25. Hyde JE. Targeting purine and pyrimidine metabolism in human apicomplexanparasites. Curr Drug Targets 2007;8:31-47. (Pubitemid 46043897)
26. Carter D, Donald RG, Roos D, Ullman B. Expression, purification, and char-acterization of uracil phosphoribosyltransferase from Toxoplasma gondii. MolBiochem Parasitol 1997;87:137-44. (Pubitemid 27283276)
27. Fox BA, Bzik DJ. De novo pyrimidine biosynthesis is required for virulence ofToxoplasma gondii. Nature 2002;415:926-9. (Pubitemid 34174756)
28. Dong CK, Patel V, Yang JC, Dvorin JD, Duraisingh MT, Clardy J, et al. Type IINADH dehydrogenase of the respiratory chain of Plasmodium falciparum andits inhibitors. Bioorg Med Chem Lett 2009;19:972-5.
29. Hurt DE, Widom J, Clardy J. Structure of Plasmodium falciparum dihydrooro-tate dehydrogenase with a bound inhibitor. Acta Crystallogr D Biol Crystallogr2006;62:312-23. (Pubitemid 44185140)
30. Liu S, Neidhardt EA, Grossman TH, Ocain T, Clardy J. Structures of human dihy-droorotate dehydrogenase in complex with antiproliferative agents. Structure2000;8:25-33. (Pubitemid 30051339)
31. Norager S, Jensen KF, Bjornberg O, Larsen S. E. coli dihydroorotate dehydroge-nase reveals structural and functional distinctions between different classes ofdihydroorotate dehydrogenases. Structure 2002;10:1211-23. (Pubitemid 35254010)
32. Deng X, Gujjar R, El Mazouni F, Kaminsky W, Malmquist NA, Goldsmith EJ,et al. Structural plasticity of malaria dihydroorotate dehydrogenase allowsselective binding of diverse chemical scaffolds. J Biol Chem 2009;284:7009-26999.
33. Malmquist NA, Gujjar R, Rathod PK, Phillips MA. Analysis of flavin oxidation andelectron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydro-genase. Biochemistry 2008;47:2466-75. (Pubitemid 351304552)
34. Phillips MA, Gujjar R, Malmquist NA, White J, El Mazouni F, Baldwin J,et al. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors withpotent and selective activity against the malaria parasite Plasmodium falcipa-rum. J Med Chem 2008;51:53-3649.